Search
for
Sort by
Research 61–90 of 534
- Alopecia areata and ritlecitinib: Unravelling response trajectories
- Excellent response to tofacitinib treatment in a patient with alopecia universalis
- II Consensus of the Brazilian Society of Dermatology for the treatment of alopecia areata
- Inibidores das Janus Associated Kinases na Terapêutica Farmacológica
- 008 Stratifying alopecia areata systemic treatments: Tailored approaches to disease severity
- Assessing Alopecia Areata Management in Poland: Challenges in Medical Practices and Patient Care
- Alopecia Areata – Effects of Treatment with Upadacitinib – Two Case Reports
- Comparative analysis of therapeutic outcomes in pediatric versus adult ophiasis-pattern alopecia areata: A review of treatment modalities and disease course
- High-throughput T cell receptor sequencing identifies clonally expanded CD8+ T cell populations in alopecia areata
- Treating Alopecia Areata: Current Practices Versus New Directions
- A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib
- Alopecia areata: medical treatments
- Safety and efficacy of tofacitinib in 97 alopecia areata patients
- Alopecia areata
- Alopecia Areata: Current Review
- Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options
- 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
- 42005 Sustained scalp, eyebrow, and eyelash hair regrowth with ritlecitinib through Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
- Clinical Outcomes of Ritlecitinib in Treatment-Refractory Alopecia Areata: A Single-Center Real-World Study
- A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
- Efficacy and Safety of Switching from Baricitinib to Ritlecitinib in Severe Alopecia Areata
- Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
- Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
- Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program
- Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older
- Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double‐blind, placebo‐controlled trial
- A Phase 1, Open‐Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6–12 Years With Alopecia Areata
- SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata
- Real-World Ritlecitinib Treatment of Severe Alopecia Areata (AA) in the US: Patient Characteristics and Physician Satisfaction
- Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials